trending Market Intelligence /marketintelligence/en/news-insights/trending/3rxrtan_azolgy3skuz8-a2 content esgSubNav
In This List

EyePoint Pharmaceuticals elects new board chairman

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


EyePoint Pharmaceuticals elects new board chairman

EyePoint Pharmaceuticals Inc., a specialty biopharmaceutical company, elected Göran Ando to be the chairman of the company's board.

Ando was appointed to the board in June 2018, according to a Sept. 10 press release. He previously held positions with Pfizer Inc., held several senior appointments at GlaxoSmithKline PLC, and most recently served as the CEO for Celltech Group Ltd.

As part of the transition, David Mazzo will step down as the non-executive chairman but will remain on the board.